Predicine BEACON TO THE PROPERTY OF THE PROPER

Introducing Next-Generation Actionable MRD

An ultra-sensitive Minimal Residual Disease (MRD) detection that is not limited by baseline tissue sample availability.


50

Mutation personalized panel

500
Actionable mutations tracked

0.005%

Limit of detection



Methods and Reporting

- Flexibiliy in baseline profiling tissue or liquid biopsy
- Ultra-sensitive in MRD detection 0.005% LOD
- Includes genome-wide copy number changes
- Longitudinally tracks up to 50 personalized mutations
- Includes analysis of 500 actionable approved therapy selection mutations

Workflow





PredicineBEACON addresses the challenges faced by conventional MRD assays

- Baseline agnostic solution: Baseline analysis can be obtained via blood, urine, or tissue
- Ultra-sensitive: Ability to identify alterations missed by less sensitive assays
- Multi-dimentional: Detects all types of DNA changes, including fusions and copy number changes
- Actionable MRD result: Upon recurrence, actionable mutation analysis will provide treatment insights

Product details



Baseline Profiling

Blood, Urine, or Tissue



Multi-Dimensional MRD Detection

Mutations, Fusions, and Copy Number Changes




Ultra Sensitivity
0.005% Limit of Detection



Actionable MRD 500 actionable mutations

MRD Detection Unbounded by Baseline Sample Availability



MRD detection with PredicineBEACON™ is not limited by baseline tissue sample availability. If available, baseline samples can be assessed using patient's blood, urine or tissue. Monitoring recurrence or progression of cancer can be achieved with a simple blood draw or urine sample. Monitoring intervals can be customized according to risk or medical necessity.